SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 45939
  • 2
    Grabmaier K, Vissers JL, De Weijert MC et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000; 85: 86570
  • 3
    Gnarra JR, Lerman MI, Zbar B, Linehan WM. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995; 22: 38
  • 4
    Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 42734
  • 5
    Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL, Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-α or interferon-α plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004; 10: 25846
  • 6
    Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 48994
  • 7
    Grabmaier K, A de Weijert MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX (G250/MN) by HIF-1α in clear cell renal cell carcinoma. Oncogene 2004; 23: 562431
  • 8
    Divgi CR, Bander NH, Scott AM et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4: 272939
  • 9
    Steffens MG, Boerman OC, Oosterwijk-Wakka JC et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 152937
  • 10
    Steffens MG, Boerman OC, De Mulder PH et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5 (Suppl.): 3268s74s
  • 11
    Divgi CR, O’Donoghue JA, Welt S et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004; 45: 141221
  • 12
    Brouwers AH, Mulders PF, De Mulder PH et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005; 23: 65408
  • 13
    Brouwers AH, Van Eerd JE, Frielink C et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 2004; 45: 32737
  • 14
    Bleumer I, Knuth A, Oosterwijk E et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90: 98590
  • 15
    Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC et al. A clinical trial with chimeric monoclonal antibody WX- G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175: 5762
  • 16
    Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 2006; 50: 3443
  • 17
    Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002; 25: 5008
  • 18
    Uemura H, Fujimoto K, Tanaka M et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006; 12: 176875